Rasal2 inhibits autophagic-exosomes secretion via regulating Rab27a in triple-negative breast cancer progression
- PMID: 40369567
- PMCID: PMC12079882
- DOI: 10.1186/s12967-025-06530-2
Rasal2 inhibits autophagic-exosomes secretion via regulating Rab27a in triple-negative breast cancer progression
Abstract
Background: Triple-negative breast cancer (TNBC) is a subtype with the worst prognosis and there is still a lack of effective treatment. Exosomes (Exos) secreted by cancer cells to tumor microenvironment play an important role in cancer progression. We have demonstrated that the function of Rasal2 in the modulation of breast cancer progression is exos-mediated, but the relationship between Rasal2 and exosome secretion remains elusive.
Methods: Rasal2 knock-out (KO) MDA-MB-231 cells were conducted by crispr-cas9 technique and Rab27a knock-down (KD) in Rasal2 KO MDA-MB-231 cells (KO + KD) were further established by siRNA-mate plus transfection Reagent. Control (CT)/KO MDA-MB-231 cells stably overexpressing GFP-LC3 were generated by using GFP-LC3 plamisd. Transmission electron microscope (TEM), nanoparticle tracking analysis (NTA) and western blot analysis (WB) were used to identify exos derived from TNBC. Confocal microscopy was used to observe the autophagic flux and the colocalization of autophagosomes and multivesicular bodies (MVBs). Co-immunoprecipitation analysis was performed to determine the interaction between Rasal2 and Rab27a. Immunohistochemical analysis were used to detect the expression levels of autophagy-related proteins in tumor tissues of xenograft mice inoculated with CT/KO/KO + KD MDA-MB-231 cells.
Results: In this paper, we found that Rasal2 KO disrupts autophagic flux and induces secretory autophagy to promote autophagic-exos secretion in TNBC. Moreover, Rasal2 inhibits the activity of Rab27a which regulates vesicles transport and fusion, and Rab27a mediates Rasal2 KO-induced autophagic-exos secretion. Additionally, Rab27a KD inhibits Rasal2 KO-induced secretory autophagy, thereby promoting TNBC progression both in vivo and in vitro.
Conclusions: Collectively, these findings delineated the role of Rab27a in TNBC progression modulated by Rasal2 through autophagy-exos pathway and suggested that it is of great significance for the early diagnosis, targeted therapy and prognosis judgement of TNBC from the perspective of tumor microenvironment.
Keywords: Autophagic-exos; Rab27a; Rasal2; Secretory autophagy; TNBC progression.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Animal experiments were approved by the Animal Ethical Committee of Qingdao University. Consent for publication: All authors agree to publish. Competing interests: The authors declare no competing interests.
Figures







Similar articles
-
Rasal2 suppresses breast cancer cell proliferation modulated by secretory autophagy.Mol Cell Biochem. 2019 Dec;462(1-2):115-122. doi: 10.1007/s11010-019-03615-7. Epub 2019 Aug 31. Mol Cell Biochem. 2019. PMID: 31473883
-
Role of Acorus calamus extract in reducing exosome secretion by targeting Rab27a and nSMase2: a therapeutic approach for breast cancer.Mol Biol Rep. 2025 Jan 15;52(1):124. doi: 10.1007/s11033-024-10203-6. Mol Biol Rep. 2025. PMID: 39812915
-
Hypoxic BMSC-derived exosomal miR-210-3p promotes progression of triple-negative breast cancer cells via NFIX-Wnt/β-catenin signaling axis.J Transl Med. 2025 Jan 9;23(1):39. doi: 10.1186/s12967-024-05947-5. J Transl Med. 2025. PMID: 39789572 Free PMC article.
-
Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells.Cancer Metastasis Rev. 2018 Sep;37(2-3):491-507. doi: 10.1007/s10555-018-9753-x. Cancer Metastasis Rev. 2018. PMID: 30091053 Review.
-
Effects and mechanisms of exosomes in microenvironment angiogenesis in breast cancer: An updated review.Oncol Res. 2025 May 29;33(6):1323-1334. doi: 10.32604/or.2024.059113. eCollection 2025. Oncol Res. 2025. PMID: 40486870 Free PMC article. Review.
References
-
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin. 2021;71(3):209–49. - PubMed
-
- Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and Long-Term survival in patients with Triple-Negative breast Cancer[J]. J Clin Oncol. 2023;41(10):1809–15. - PubMed
-
- Mehraj U, Mushtaq U, Mir MA, et al. Chemokines in triple-negative breast cancer heterogeneity: new challenges for clinical implications[J]. Semin Cancer Biol. 2022;86(Pt 2):769–83. - PubMed
-
- Hamdy NM, Basalious EB, El-Sisi MG, et al. Advancements in current one-size-fits-all therapies compared to future treatment innovations for better improved chemotherapeutic outcomes: a step-toward personalized medicine[J]. Curr Med Res Opin. 2024;40(11):1943–61. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous